Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Other Non Operating Income: 2021-2025

Historic Other Non Operating Income for Rhythm Pharmaceuticals (RYTM) over the last 4 years, with Sep 2025 value amounting to $274,000.

  • Rhythm Pharmaceuticals' Other Non Operating Income fell 74.82% to $274,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 79.28%. This contributed to the annual value of $8.9 million for FY2024, which is 4584.21% up from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Other Non Operating Income is $274,000, which was down 82.61% from $1.6 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Other Non Operating Income's 5-year high stood at $100.0 million during Q1 2021, with a 5-year trough of -$644,000 in Q1 2025.
  • Its 3-year average for Other Non Operating Income is $1.2 million, with a median of $399,000 in 2024.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Other Non Operating Income surged by 52,452.94% in 2024, and later tumbled by 222.90% in 2025.
  • Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Other Non Operating Income stood at $100.0 million in 2021, then plummeted by 100.23% to -$420,000 in 2022, then surged by 233.10% to $559,000 in 2023, then skyrocketed by 784.28% to $1.1 million in 2024, then slumped by 74.82% to $274,000 in 2025.
  • Its last three reported values are $274,000 in Q3 2025, $1.6 million for Q2 2025, and -$644,000 during Q1 2025.